Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Liver Diseases

Free Subscription 29.09.2025 2 BMC Gastroenterol 1 Br J Surg 1 Eur J Pediatr 1 Gastroenterology 2 J Gastroenterol 4 J Hepatol 1 Oncogene 1 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Gastroenterol

1. JAFREE SR, Naveed A, Ahsan H, Burhan SK, et al
   Predictors of health-seeking behavior in patients with chronic liver disease and a comparison of health-seeking based on patient-type.
   BMC Gastroenterol. 2025;25:642.
   PubMed         Abstract available
   
   
2. ZHANG Y, Luo M, Ming Y
   Global burden of cirrhosis and other chronic liver diseases caused by specific etiologies from 1990 to 2021.
   BMC Gastroenterol. 2025;25:641.
   PubMed         Abstract available
   
   

   
   Br J Surg

3. REESE T, Bjork D, Longva AMH, Kiim KS, et al
   Oncological safety of portal vein embolization without prior tumour clearance in the future liver remnant followed by one-stage hepatectomy for bilateral colorectal liver metastases.
   Br J Surg. 2025;112:znaf198.
   PubMed         Abstract available
   
   

   
   Eur J Pediatr

4. LIN DC, Hou JY, Tseng CK, Tsai PS, et al
   The changes in imaging following proton beam therapy for pediatric hepatoblastoma.
   Eur J Pediatr. 2025;184:626.
   PubMed         Abstract available
   
   

   
   Gastroenterology

5. FOX D, Xie J, Burwinkel JL, Adams JM, et al
   Adeno-associated Virus-mediated Silencing of Sox4 Leads to Long-Term Amelioration of Liver Phenotypes in Mouse Models of Alagille Syndrome.
   Gastroenterology. 2025;169:1000-1016.
   PubMed         Abstract available
   
   

   
   J Gastroenterol

6. FUJII H, Uchida-Kobayashi S, Kanamori A, Nadatani Y, et al
   Defining optimal fatty liver index thresholds for MASLD and MetALD using controlled attenuation parameter as reference.
   J Gastroenterol. 2025;60:1296-1309.
   PubMed         Abstract available
   
   
7. LEE J, Cha JH, Cho HS, Yang K, et al
   The PNPLA3 I148M variant is associated with immune cell infiltration and advanced fibrosis in MASLD: a prospective genotype-phenotype study.
   J Gastroenterol. 2025;60:1284-1295.
   PubMed         Abstract available
   
   

   
   J Hepatol

8. OCHOA-ALLEMANT P, Hubbard RA, Kaplan DE, Serper M, et al
   Cause-specific mortality in patients with steatotic liver disease in the United States.
   J Hepatol. 2025;83:860-869.
   PubMed         Abstract available
   
   
9. ISBISTER G, Chiew A, Buckley N, Harris K, et al
   A non-inferiority randomised controlled trial of a Shorter Acetylcysteine Regimen for Paracetamol Overdose - the SARPO trial.
   J Hepatol. 2025 May 23:S0168-8278(25)02206-8. doi: 10.1016/j.jhep.2025.
   PubMed         Abstract available
   
   
10. DIAZ LA, Alazawi W, Agrawal S, Arab JP, et al
    High inherited risk predicts age-associated increases in fibrosis in patients with MASLD.
    J Hepatol. 2025;83:849-859.
    PubMed         Abstract available
    
    
11. RIMASSA L, Chan SL, Sangro B, Lau G, et al
    Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC.
    J Hepatol. 2025;83:899-908.
    PubMed         Abstract available
    
    

    
    Oncogene

12. TSUCHIYA H, Hanaki T, Sakabe T, Tokuyasu N, et al
    Immune evasion from macrophages by NEAT1-induced CD24 in liver cancer.
    Oncogene. 2025;44:3652-3664.
    PubMed         Abstract available
    
    

    
    PLoS One

13. YUAN J, Chen Z, Gu Y, Liang Y, et al
    Effects of alcohol consumption on the prevalence and incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    PLoS One. 2025;20:e0330105.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

14. YUAN Y, Niu Y, Huang Z, Shi Y, et al
    USP14-mediated metabolic competition impairs CD8+ T cell immunosurveillance in hepatocellular carcinoma.
    Proc Natl Acad Sci U S A. 2025;122:e2510576122.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.